Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBIT Margin (2022 - 2025)

Historic EBIT Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 162.54%.

  • InMed Pharmaceuticals' EBIT Margin fell 253500.0% to 162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 167.4%, marking a year-over-year decrease of 210800.0%. This contributed to the annual value of 160.77% for FY2025, which is 175000.0% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported EBIT Margin of 162.54% as of Q3 2025, which was down 253500.0% from 139.49% recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' EBIT Margin registered a high of 20.99% during Q2 2023, and its lowest value of 1626.64% during Q4 2021.
  • In the last 5 years, InMed Pharmaceuticals' EBIT Margin had a median value of 186.09% in 2024 and averaged 463.0%.
  • Per our database at Business Quant, InMed Pharmaceuticals' EBIT Margin surged by 12456200bps in 2023 and then plummeted by -1375500bps in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' EBIT Margin (Quarter) stood at 1626.64% in 2021, then surged by 71bps to 471.26% in 2022, then surged by 72bps to 132.64% in 2023, then tumbled by -53bps to 202.75% in 2024, then grew by 20bps to 162.54% in 2025.
  • Its EBIT Margin was 162.54% in Q3 2025, compared to 139.49% in Q2 2025 and 169.43% in Q1 2025.